Prophylaxis of Pneumocystis jiroveci pneumonia (PJP) with trimethoprim/sulfamethoxazole is a standard of care for children with hematologic malignancies, while its use in solid tumor patients is still debated. A retrospective study focusing on the use of PJP prophylaxis in patients with solid tumors was performed among 16 AIEOP centers: 1046/2863 patients did not receive prophylaxis and no cases of PJP were reported.
Prophylaxis with Trimethoprim/Sulfamethoxazole Is Not Necessary in Children with Solid Tumors Treated with Low-medium Intensity Chemotherapy / Meazza C.; Galaverna F.; Petris M.G.; Zama D.; La Spina M.; Muggeo P.; Ziino O.; Cellini M.; Soncini E.; Barone A.; De Santis R.; Perruccio K.; Mura R.; Pascale S.; Mercolini F.; Cesaro S.. - In: THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. - ISSN 0891-3668. - STAMPA. - 40:4(2021), pp. 354-355. [10.1097/INF.0000000000003044]
Prophylaxis with Trimethoprim/Sulfamethoxazole Is Not Necessary in Children with Solid Tumors Treated with Low-medium Intensity Chemotherapy
Zama D.;Cellini M.;Soncini E.;
2021
Abstract
Prophylaxis of Pneumocystis jiroveci pneumonia (PJP) with trimethoprim/sulfamethoxazole is a standard of care for children with hematologic malignancies, while its use in solid tumor patients is still debated. A retrospective study focusing on the use of PJP prophylaxis in patients with solid tumors was performed among 16 AIEOP centers: 1046/2863 patients did not receive prophylaxis and no cases of PJP were reported.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
